Literature DB >> 11806489

Diagnosis, classification, and pathogenesis of diabetes mellitus.

H E Lebovitz1.   

Abstract

Diabetes mellitus is a metabolic disorder that is characterized by inappropriate hyperglycemia and is associated with both acute and chronic complications. Currently, diabetes mellitus is diagnosed by blood or plasma glucose levels. A random plasma glucose level > or = 200 mg/dL in an individual with classic symptoms is sufficient to make the diagnosis. Otherwise, a fasting plasma glucose level > or = 126 mg/dL or a 2-hour plasma glucose level > or = 200 mg/dL after an oral glucose challenge of 75 g on 2 occasions is sufficient evidence upon which to diagnose diabetes mellitus. The major types of diabetes mellitus are type 1 diabetes (insulin deficient) and type 2 diabetes (combination of insulin resistance and insulin deficiency). In both types, there is a genetic predisposition as well as environmental factors that contribute to the expression of the genetic predisposition. In type 1 diabetes, the primary abnormality is extensive deficiency of beta cell function. In type 2 diabetes, insulin resistance occurs, and the marked compensatory increases in insulin secretion necessary to maintain normal glucose tolerance cannot be achieved or maintained. As beta cell function continues to decrease, the individual progresses from normal glucose tolerance to impaired glucose tolerance to diabetes with primarily postprandial hyperglycemia to diabetes with fasting hyperglycemia. Drugs can cause diabetes by interfering with beta cell insulin secretion, by increasing insulin resistance, or by a combination of both. Atypical antipsychotic drugs have been reported to cause diabetic ketoacidosis, obesity and insulin resistance, type 2 diabetes, and hypertriglyceridemia. A monitoring system should be in place in patients started on treatment with these agents to detect metabolic abnormalities as they are evolving so that adequate and timely treatment can be initiated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11806489

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

Review 1.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  Prevalence of overweight and obesity and their association with hypertension and diabetes mellitus in an Indo-Asian population.

Authors:  Tazeen H Jafar; Nish Chaturvedi; Gregory Pappas
Journal:  CMAJ       Date:  2006-10-24       Impact factor: 8.262

Review 3.  [Atypical antipsychotics and metabolic syndrome].

Authors:  Andreas Baranyi; Renè Yazdani; Alexandra Haas-Krammer; Alexandra Stepan; Hans-Peter Kapfhammer; Hans-Bernd Rothenhäusler
Journal:  Wien Med Wochenschr       Date:  2007

Review 4.  Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.

Authors:  Kimberly A Stigler; Marc N Potenza; David J Posey; Christopher J McDougle
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

5.  Prevalence of Diabetes Mellitus and Its Risk Factors among Individuals Aged 15 Years and Above in Mizan-Aman Town, Southwest Ethiopia, 2016: A Cross Sectional Study.

Authors:  Shiferaw Birhanu Aynalem; Ayalew Jejaw Zeleke
Journal:  Int J Endocrinol       Date:  2018-04-26       Impact factor: 3.257

6.  Comparison of Salivary Cortisol Level in Type 2 Diabetic Patients and Pre-Diabetics with Healthy People.

Authors:  Maedeh Salehi; Abbas Mesgarani; Soosan Karimipour; Shaghayegh Zahed Pasha; Zahra Kashi; Saeed Abedian; Mahmoud Mousazadeh; Tahereh Molania
Journal:  Open Access Maced J Med Sci       Date:  2019-07-25

7.  Meta-analysis of studies on depression prevalence among diabetes mellitus patients in Africa.

Authors:  Ropo Ebenezer Ogunsakin; Oludayo O Olugbara; Sibusiso Moyo; Connie Israel
Journal:  Heliyon       Date:  2021-05-21

8.  Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats.

Authors:  Feng-Ching Hsieh; Chia-Lin Lee; Chee-Yin Chai; Wan-Tzu Chen; Ying-Chen Lu; Ching-Shuang Wu
Journal:  Nutr Metab (Lond)       Date:  2013-04-17       Impact factor: 4.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.